The Majorana Demonstrator radioassay program Abgrall, N.; Arnquist, I.J.; Avignone, F.T. ...
Nuclear instruments & methods in physics research. Section A, Accelerators, spectrometers, detectors and associated equipment,
08/2016, Letnik:
828
Journal Article
Recenzirano
Odprti dostop
The Majorana collaboration is constructing the Majorana Demonstrator at the Sanford Underground Research Facility at the Homestake gold mine, in Lead, SD. The apparatus will use Ge detectors, ...enriched in isotope 76Ge, to demonstrate the feasibility of a large-scale Ge detector experiment to search for neutrinoless double beta decay. The long half-life of this postulated process requires that the apparatus be extremely low in radioactive isotopes whose decays may produce backgrounds to the search. The radioassay program conducted by the collaboration to ensure that the materials comprising the apparatus are sufficiently pure is described. The resulting measurements from gamma-ray counting, neutron activation and mass spectroscopy of the radioactive-isotope contamination for the materials studied for use in the detector are reported. We interpret these numbers in the context of the expected background for the experiment.
Focal-plane detector system for the KATRIN experiment Amsbaugh, J.F.; Barrett, J.; Beglarian, A. ...
Nuclear instruments & methods in physics research. Section A, Accelerators, spectrometers, detectors and associated equipment,
04/2015, Letnik:
778, Številka:
C
Journal Article
Recenzirano
Odprti dostop
The focal-plane detector system for the KArlsruhe TRItium Neutrino (KATRIN) experiment consists of a multi-pixel silicon p-i-n-diode array, custom readout electronics, two superconducting solenoid ...magnets, an ultra high-vacuum system, a high-vacuum system, calibration and monitoring devices, a scintillating veto, and a custom data-acquisition system. It is designed to detect the low-energy electrons selected by the KATRIN main spectrometer. We describe the system and summarize its performance after its final installation.
A search has been made for neutrinos from the hep reaction in the Sun and from the diffuse supernova neutrino background (DSNB) using data collected during the first operational phase of the Sudbury ...Neutrino Observatory, with an exposure of 0.65 ktons yr. For the hep neutrino search, two events are observed in the effective electron energy range of 14.3 MeV < T sub(eff) < 20 MeV, where 3.1 background events are expected. After accounting for neutrino oscillations, an upper limit of 2.3 x 10 super(4) cm super(-2) s super(-1) at the 90% confidence level is inferred on the integral total flux of hep neutrinos. For DSNB neutrinos, no events are observed in the effective electron energy range of 21 MeV < T sub(eff) < 35 MeV, and, consequently, an upper limit on the u sub(e) component of the DSNB flux in the neutrino energy range of 22.9 MeV < E sub(u)< 36.9 MeV of 70 cm super(-2) s super(-1) is inferred at the 90% confidence level. This is an improvement by a factor of 6.5 on the previous best upper limit on the hep neutrino flux and by 2 orders of magnitude on the previous upper limit on the u sub(e) component of the DSNB flux.
Abstract
The glycation gap (GGap) and the similar hemoglobin glycation index (HGI) define consistent differences between glycated hemoglobin and actual glycemia derived from fructosamine or mean ...blood glucose, respectively. Such a disparity may be found in a substantial proportion of people with diabetes, being >1 U of glycated HbA1c% or 7.2 mmol/mol in almost 40% of estimations. In this review we define these indices and explain how they can be calculated and that they are not spurious, being consistent in individuals over time. We evaluate the evidence that GGap and HGI are associated with variation in risk of complications and mortality and demonstrate the potential for clinical error in the unquestioning use of HbA1c. We explore the underlying etiology of the variation of HbA1c from mean glucose in blood plasma, including the potential role of enzymatic deglycation of hemoglobin by fructosamine-3-kinase. We conclude that measurement of GGap and HGI are important to diabetes clinicians and their patients in individualization of therapy and the avoidance of harm arising from consequent inappropriate assessment of glycemia and use of therapies.
PDF
